Colistimethate Pregnancy and Breastfeeding Warnings
Brand names: Coly Mycin M
Medically reviewed by Drugs.com. Last updated on Apr 9, 2024.
Colistimethate Pregnancy Warnings
Colistimethate has been assigned to pregnancy category C by the FDA. In animal studies, colistimethate was teratogenic and embryotoxic in rabbits, but not teratogenic in rats. There are no controlled data in human pregnancy. Colistimethate crosses the placenta and should only be given during pregnancy when benefit outweighs risk.
Colistimethate Breastfeeding Warnings
Colistimethate is excreted into human milk in small amounts (milk-to-plasma ratio 0.17 to 0.18). The possibility of bowel flora modification and interference with culture results should be considered. The manufacturer recommends that caution be used when administering colistimethate to breast-feeding women.
See also
References for pregnancy information
- (2001) "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis
- Briggs GG, Freeman RK, Yaffe SJ.. (2005) "Drugs in Pregnancy and Lactation." Philadelphia, PA: Lippincott Williams & Wilkins
References for breastfeeding information
- (2001) "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis
- Briggs GG, Freeman RK, Yaffe SJ.. (2005) "Drugs in Pregnancy and Lactation." Philadelphia, PA: Lippincott Williams & Wilkins
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
